1Hurwitz H ,renbaeher L, Novotny W, et al. Bevacizumab plus irinotecan,fluorouracil,and leueovorin for metastatic colorectal cancer [ J]. N Engl J Med,2004,350:2335 - 2342.
3Robert L. Avery, Dante J, et al. Intravitreal Bevacizumab for Neovas- cular Age - Related Macular Degeneration [ J ]. Ophthalmol, 2006, 113:363 - 372.
6Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab, safety survery: using the intemet to assess drug safety world - wide[ J]. Ophthalmol,2006,90( 11 ) : 1344 - 1349.
6Tolentino MJ, Miller JW,Gragoudas ES,et al.lntravitreous injection of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.Ophthalmology, 1996,103( 11): 1820-1828.
7Tolentino MJ,McLeod DS,Taomoto M,et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.Am J Ophthalmol,2002,133(3):373-385.
8Senger DR,Galli SJ, Dvorak AM,et al.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983,219(4587):983 -985.
9Leung DW,Caehianes G,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen.Science, 1989,246(4935): 1306 - 1309.
10Cross MJ,Claeason-Welsh L.FGF and VEGF function in angiogenesis:signalling pathways,biological responses and therapeutic inhibition. Trends Pharmacol Sci,2001,22(4):201 -207.
3Tolentino MJ. Current molecular understanding and future treat- ment strategies for pathologic ocular neovascularization. Curr Mol Med, 2009,9:973 - 981.
4Aiello LP, Brucker A J, Chang S, et al. Evolving guidelines for intravitreous injections. Retina, 2004,24 : S3 - S19.
5Frenkel RE, Haji SA, La M, et al. A protocol for the retina sur- geong safe initial intravitreal injections. Clin Ophthalmol, 2010, 4:1279 - 1285.
6Korobelnik J, Weber M, Cohen S. Guidelines for intravitreal in- jections. J Fran? ais Ophtalmol, 2009,32 :e1 -e2.
7Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti - vascular endothelial growth factor agents. Am J Ophthalmol, 2008,146:930 - 934.
8Tailor R, Beasley R, Yang Y, et al. Evaluation of patients' expe- riences at different stages of the intravitreal injection procedure - what can be improved? Clinical Ophthalmology, 2011,5:1499 - 1502.
